Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has issued an update.
EBR Systems, developer of the WiSE wireless cardiac pacing system, will showcase its technology and clinical progress at the Heart Rhythm 2026 conference in Chicago, underscoring its focus on improving cardiac resynchronisation therapy for heart failure patients. The company will feature the WiSE System in multiple scientific sessions and symposia, highlighting early U.S. commercial experience following FDA approval, new reimbursement milestones, and ongoing post-approval and leadless CRT clinical studies that support broader adoption of its leadless pacing approach.
Management positions this conference as a pivotal moment to demonstrate how its totally leadless and physiologic pacing strategies could enhance outcomes and solidify EBR Systems’ position in the cardiac rhythm management market. With WiSE currently the only wireless endocardial left-ventricular pacing system in clinical use and commercially available in the U.S., the company’s growing clinical and reimbursement footprint may strengthen its competitive standing and appeal to clinicians, hospitals, and investors focused on next‑generation heart failure therapies.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.47 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
EBR Systems, Inc. is a Silicon Valley-based medical technology company focused on treating cardiac rhythm disease through wireless cardiac pacing solutions. Its patented Wireless Stimulation Endocardially (WiSE) technology delivers endocardial left-ventricle pacing for heart failure patients needing cardiac resynchronisation therapy, with future applications potentially extending to bradycardia and non-cardiac indications.
Average Trading Volume: 541,281
Technical Sentiment Signal: Sell
Current Market Cap: A$29.94M
See more data about EBR stock on TipRanks’ Stock Analysis page.